Biotie Therapies Oyj

Type: Company
Name: Biotie Therapies Oyj (Biotie Therapies Corp)
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Turku’s biotech industry taking on the world

The BioTurku biotech cluster, located in Turku, Finland, is the nation’s leading innovator in the field and has its sights set on conquering global markets. — The future looks bright, with the markets growing steadily, says Director Tero Piispanen.Some ... [Published Good News From Finland - Apr 10 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 2 reports

RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. AND ORGANIZATION OF THE BOARD

at 12.30 p.m.RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. ANDORGANIZATION OF THE BOARDThe Annual General Meeting of Biotie Therapies Corp. was held on 3 April 2014.Adoption of financial statements for the financial year 1 January ... [Published GlobeNewswire - Apr 03 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

Biotie Therapies Oyj : Biotie: Change in the number of votes

at 2.45 pmBiotie: Change in the number of votesBiotie Therapies Corp. ("Biotie" or the "Company") has conveyed Biotie shares held as treasury shares, that were issued on 2 January 2014, pursuant to the Stock Option Plan 2011 and the Equity Incentive Plan ... [Published Investegate - Apr 03 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

Biotie Therapies names William M. Burns Chairman; elects PricewaterhouseCoopers Oy and Samuli Perala Authorised Public Accountant as auditors

Biotie Therapies Oyj:Elects William M. Burns Chairman of the Board.Elects PricewaterhouseCoopers Oy and Samuli Perala Authorised Public Accountant as auditors of the company. ... [Published Reuters - Apr 03 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

BIOTIE THERAPIES : Resolutions of the annual general meeting of biotie therapies corp. and organization of the board

at 12.30 p.m. RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. ANDORGANIZATION OF THE BOARDThe Annual General Meeting of Biotie Therapies Corp. was held on 3 April 2014 .Adoption of financial statements for the financial year 1 January ... [Published 4 Traders - Apr 03 2014]
First reported Apr 01 2014 - Updated Apr 02 2014 - 2 reports

ALLIANCE PHARMA : Appointment of Non-Executive Director

Release date- 01042014 - Alliance Pharma plc ('Alliance' or the 'Company'), the specialty pharmaceutical company, is pleased to announce the appointment of David Cook as an independent Non-executive Director of the Company, effective 1 April 2014 .David ... [Published 4 Traders - Apr 02 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Alliance Pharma welcomes Cook to board

David Cook has joined Alliance Pharma ( LON:APH ) as a non-executive director with effect from today (April 1). Cook, an accountant and chemistry graduate from Oxford University, is currently the chief financial officer of Helsinki-listed drug development ... [Published Proactiveinvestors United Kingdom RSS feed - Apr 01 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 3 reports

UCB to Return Tozadenant Rights

UCB  ( UCBJF ) has several late stage candidates including romosozumab in osteoporosis in post-menopausal women, brivaracetam as adjunctive therapy for the treatment of partial onset seizures in adults with epilepsy, and epratuzumab in systemic lupus ... [Published Yahoo! Finance - Mar 26 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

UCB Pharma to return global rights of tozadenant to Biotie

Belgium-based biopharmaceutical firm UCB Pharma (UCB) will return global rights of tozadenant (SYN115), a selective inhibitor of the adenosine 2a (A2a) receptor intended for the treatment of Parkinson’s disease, to Finland-based Biotie Therapies.The decision ... [Published Pharmaceutical Business Review - Mar 25 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 7 reports

BioTie Therapies Corp. To Regain Global Rights To Tozadenant From UCB Pharma

. Biotie Therapies Corp. announced today that UCB Pharma S.A. (UCB) will return global rights to tozadenant to Biotie. Tozadenant (SYN115), a selective inhibitor of the adenosine 2a (A2a) receptor, has delivered clinically relevant and statistically highly ... [Published BioSpace - Mar 21 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

BRIEF-U C B returns global rights to Tozadenant to Biotie

6:10am GMTBRUSSELS, March 21 (Reuters) - U C B SA : * UCB returns global rights to Tozadenant to Biotie * Portfolio decision by UCB in light of its pipeline priorities biotie will continue to develop Tozadenant in parkinson's disease * Tozadenant is scheduled ... [Published Reuters UK - Mar 21 2014]
First reported Mar 11 2014 - Updated Mar 11 2014 - 2 reports

Biotie invests in Alzheimer’s drug SYN120 as it drops epilepsy pathway

Finland-based Biotie Therapies (Nasdaq OMX: BTH1V), which is focused on neurodegenerative and psychiatric disorders, has completed further review of its pipeline.The company published a review in September which highlighted the approval and launch of ... [Published Pharma Letter - Mar 11 2014]

Quotes

Boston, MA -- (SBWIRE) -- 04/16/2014 -- Global Markets Direct's, "Rheumatoid ', provides an overview of the Rheumatoid Arthritis's therapeutic pipeline."
Release date- 01042014 - Alliance Pharma plc ( "Alliance' or the 'Company'), the specialty pharmaceutical company, is pleased to announce the appointment of David Cook as an independent Non-executive Director of the Company, effective 1 April 2014 ."
"We respect UCB's portfolio based decision, and appreciate its significant investment and commitment to the tozadenant program to-date. Owning full global rights to tozadenant will enable Biotie to evaluate the most suitable development strategy for this Phase III-ready asset to maximize its value to our shareholders. As part of this evaluation we will consider other partners to assist us in the development and commercialization of this novel compound. We remain convinced that tozadenant will provide significant and clinically meaningful benefits to Parkinson's patients based on the robust and positive Phase IIb data, that we have already reported" says Timo Veromaa, president and chief executive of Biotie
"Owning full global rights to tozadenant will enable Biotie to evaluate the most suitable development strategy for this Phase 3 ready asset to maximize its value to our shareholders" Veromaa said

More Content

All (55) | News (31) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (1) | Press Releases (23)
sort by: Date | Relevance
Rheumatoid Arthritis - Pipeline Review, H1 2014... [Published Digital Journal - 5 hours ago]
New Market Research Report: Alzheimer's Disease... [Published SBWire - Apr 15 2014]
Global parkinson's disease market forecast to d... [Published PR inside - Apr 11 2014]
Turku’s biotech industry taking on the world [Published Good News From Finland - Apr 10 2014]
Biotie Therapies Oyj : Biotie: Change in the nu... [Published Investegate - Apr 03 2014]
Biotie Therapies names William M. Burns Chairma... [Published Reuters - Apr 03 2014]
RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BI... [Published GlobeNewswire - Apr 03 2014]
RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BI... [Published MoneyAM - Apr 03 2014]
BIOTIE THERAPIES : Resolutions of the annual ge... [Published 4 Traders - Apr 03 2014]
ALLIANCE PHARMA : Appointment of Non-Executive ... [Published 4 Traders - Apr 02 2014]
Alliance Pharma Announces Appointment Of Non-Ex... [Published Pharmacy Choice - Apr 01 2014]
Executive Q&A: Epigenomics’ chief executive Dr ... [Published Pharma Letter - Apr 01 2014]
Alliance Pharma welcomes Cook to board [Published Proactiveinvestors United Kingdom RSS feed - Apr 01 2014]
UCB to Return Tozadenant Rights [Published Yahoo! Finance - Mar 26 2014]
Biotie to regain global rights to tozadenant fr... [Published Pharma Letter - Mar 26 2014]
Biotie Therapies: Seeking A Smooth Transition [Published Investing.com - Mar 26 2014]
UCB Pharma to return global rights of tozadenan... [Published Pharmaceutical Business Review - Mar 25 2014]
BioTie Therapies Corp. To Regain Global Rights ... [Published BioSpace - Mar 21 2014]
Biotie to regain global rights to tozadenant fr... [Published FierceBiotech - Mar 21 2014]
Biotie to regain global rights to tozadenant fr... [Published Reuters UK - Mar 21 2014]
Biotie to regain global rights to tozadenant [Published Stock Market Wire - Mar 21 2014]
Biotie to regain global rights to tozadenant [Published Interactive Investor - Mar 21 2014]
UCB : returns global rights to tozadenant to Bi... [Published 4 Traders - Mar 21 2014]
BRIEF-U C B returns global rights to Tozadenant... [Published Reuters UK - Mar 21 2014]
Biotie to regain global rights to tozadenant fr... [Published GlobeNewswire: Acquisitions News - Mar 21 2014]
Biotie to regain global rights to tozadenant fr... [Published NASDAQ OMX - Mar 21 2014]
BIOTIE THERAPIES : The Lines Between Purificati... [Published 4 Traders - Mar 14 2014]
Biotie invests in Alzheimer’s drug SYN120 as it... [Published Pharma Letter - Mar 11 2014]
Biotie Therapies: Adjusted To €235M, €0.52 Per ... [Published Investing.com - Mar 11 2014]
Biotie's Financial Statement Report and Corpora... [Published GlobeNewswire: Advertising News - Mar 04 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
Biotie to regain global rights to tozadenant fr... [Published GlobeNewswire: Acquisitions News - Mar 21 2014]
Biotie's Financial Statement Report and Corpora... [Published GlobeNewswire: Advertising News - Mar 04 2014]
INVITATION TO THE ANNUAL GENERAL MEETING OF BIO... [Published GlobeNewswire: Advertising News - Feb 28 2014]
Biotie: Change in the number of votes [Published GlobeNewswire: Metals News - Jan 28 2014]
BIOTIE THERAPIES CORP: DIRECTED ISSUE [Published GlobeNewswire: Acquisitions News - Jan 08 2014]
1 2 3 4 5
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.